Limb-Girdle Muscular Dystrophy Type 2I in Norway

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

106 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-06

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Key goals are to establish the natural history of limb-girdle muscular dystrophy type 2I (LGMD 2I) and identify feasible and sensitive tools and biomarkers to measure disease affection and progression, determine the Norwegian LGMD 2I prevalence, carrier frequency and genotypes, and to assess health-related quality of life in the Norwegian LGMD 2I population.

Main aims are to facilitate future clinical trials and contribute to good clinical practice with suitable methodology and to complete health and social care in order to optimize the function and quality of daily living of the patient group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Duchenne Muscular Dystrophy < 18y in Norway: Genotype/Phenotype, Growth, Puberty, Bone Health and Quality of Life.

NCT01963897

Duchenne Muscular Dystrophy

COMPLETED

Limb Girdle Muscular Dystrophy (LGMD) Natural History

NCT01783509

Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)

COMPLETED

Evaluation of Limb-Girdle Muscular Dystrophy

NCT00893334

Becker Muscular Dystrophy Limb-Girdle Muscular Dystrophy, Type 2A (Calpain-3 Deficiency) Limb-Girdle Muscular Dystrophy, Type 2B (Miyoshi Myopathy, Dysferlin Deficiency) +1 more

COMPLETED

Long-Term Development of Muscular Dystrophy Outcome Assessments

NCT05989620

LGMD2C LGMD2D LGMD2E +26 more

RECRUITING

Natural History Study of Patients With Limb-Girdle Muscular Dystrophy 2I

NCT03842878

LGMD2I

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A single-center study with Norwegian nationwide enrollment. Data is based on questionnaires, patient journals, clinical examination, a set of functional tests and biomarkers, and patient reported outcomes. Clinical/ paraclinical tests are repeated after 2-years in order to measure disease progression. Both skeletal muscle, heart and respiratory function will be examined. At baseline there will also be performed a sleep study in order to find if they are prone to sleep-disordered breathing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Limb Girdle Muscular Dystrophy, Type 2I Limb Girdle Muscular Dystrophy Muscular Dystrophies Limb Girdle Muscular Dystrophy R9 FKRP-related

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Genetical confirmed limb-girdle muscular dystrophy type 2I in Norway
* Live in Norway
* Written consent

Exclusion Criteria

* Children \< 16 years are excluded from the assessment of quality of life and from the clinical/paraclinical part, but may contribute with information through questionnaires and patient journal.

The study of prevalence and genotypes is anonymous and consent independent and will include everyone that is genetically LGMD 2I-confirmed in Norway.

Eligible Sex

ALL

Accepts Healthy Volunteers

No